@5_utr @marklewismd @brunolarvol @MarkYarchoan @MSKCancerCenter @NEJM Relationship between TMB and outcome is nonlinear see Figure 1 https://t.co/ezpz0d2xof I need to publish my own analysis of some data which shows nonlinearity too! I really wouldn't thre
@5_utr @DrYukselUrun @NatureGenet @DrChoueiri @neerajaiims @VivekSubbiah @montypal @AlbigesL @FabioSchutz78 @g_develasco @cdanicas @OncoBellmunt @apolo_andrea I really wouldn't threshold TMB, never do it...it has a nonlinear relationship to outcome see Fig
@GeneCollector @OncoAlert Let me guess - N publications saying they have identified the magic cutpoint in TMB, and N different cutpoints 😜 Good thread 🧵 here
RT @hilseth_mistrov: @5_utr @marklewismd @MSKCancerCenter @NEJM I took data from this: https://t.co/ezpz0d2xof and found this! I would not…
@5_utr @marklewismd @MSKCancerCenter @NEJM I took data from this: https://t.co/ezpz0d2xof and found this! I would not attempt to dichotomise this marker in any way and I actually think its useless if its relationship are highly non-linear to outcome https:
@5_utr @marklewismd @MSKCancerCenter @NEJM I'd be careful with thersholdling TMB - this paper highlights non-linear relationship: https://t.co/ezpz0d2xof and its not a on-off... https://t.co/SszVnwXufD
RT @VivekSubbiah: High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers @Dr_R_K…
RT @VivekSubbiah: High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers @Dr_R_K…
RT @VivekSubbiah: High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers @Dr_R_K…
High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers @Dr_R_Kurzrock https://t.co/QMUzFUOOaz
RT @MCT_AACR: Is #TumorMutationalBurden (TMB) prognostic biomarker for outcomes in immunotherapy-naïve patients? Riviere et al find that T…
Is #TumorMutationalBurden (TMB) prognostic biomarker for outcomes in immunotherapy-naïve patients? Riviere et al find that TMB may have utility as a prognostic #Biomarker. @UCSDHealth https://t.co/ONOVPBo1ov https://t.co/ONxYeXN7Vv
Is #TumorMutationalBurden (TMB) prognostic biomarker for outcomes in immunotherapy-naïve patients? Riviere et al find that TMB may have utility as a prognostic #Biomarker. @UCSDHealth https://t.co/yroRDE82s1 https://t.co/GTZpLicVEi
Is #TumorMutationalBurden (TMB) prognostic biomarker for outcomes in immunotherapy-naïve patients? Riviere et al find that TMB may have utility as a prognostic #Biomarker. @UCSDHealth https://t.co/zXlEmVqOdL https://t.co/ddBmEkruFp
Is #TumorMutationalBurden (TMB) prognostic biomarker for outcomes in immunotherapy-naïve patients? Riviere et al find that TMB may have utility as a prognostic #Biomarker. @UCSDHealth https://t.co/24Sfm1j23w https://t.co/LM1KnONexL
High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers https://t.co/kWE1LJ0yF7
Is #TumorMutationalBurden (TMB) prognostic biomarker for outcomes in immunotherapy-naïve patients? Riviere et al find that TMB may have utility as a prognostic #Biomarker. @UCSDHealth https://t.co/CY7yopaZE0 https://t.co/sMfyaKghIU
Is #TumorMutationalBurden (TMB) a prognostic biomarker for outcomes in immunotherapy-naïve patients? Riviere et al find that TMB may have utility as a prognostic #Biomarker. @UCSDHealth https://t.co/xI864jD6E6 https://t.co/ITDMFyh98I